Phase III DeLLphi-304 results show T-cell engager Imdelltra (tarlatamab) delivers superior overall survival, improved ...

KØBENHAVN, DK / ACCESS Newswire / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

We tested more than 50 face moisturizers over the course of five weeks. Our six winners work for all skin types and offer ...

ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod; RHO data show efgartigimod achieved susta ...

KØBENHAVN, DK / ACCESS Newswire / June 10, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company focused on precision c ...

Merck reports positive results from the first two phase 3 CORALreef trials of enlicitide decanoate to treat adults with hyperlipidemia: Rahway, New Jersey Tuesday, June 10, 2025, ...

This year's Brian G.M. Durie Outstanding Achievement Awardee is Sonja Zweegman, MD, PhD, Head of the Department of Hematology ...

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses the trial design of a study comparing amivantamab with standard chemotherapy to potentially improve treatment ...

RCSI University of Medicine and Health Sciences has announced the appointment of Professor Garry Duffy as the university’s ...

The CDC’s Advisory Committee on Immunization Practices is expected to meet later in June to issue recommendations for use.

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...